bioRxivImmunology
The Regulation of Nucleic Acid Vaccine Responses by the Microbiome
A. M. F. Johnson, K. Hager, M.-G. Alameh, P. Van, N. Potchen, K. Mayer-Blackwell, A. Fiore-Gartland, S. Minot, P. J. C. Lin, Y. K. Tam, D. Weissman, J. G. Kublin
Abstract
SummaryNucleic acid vaccines, including both RNA and DNA platforms, are key technologies that have considerable promise in combating both infectious disease and cancer. However, little is known about the extrinsic factors that regulate nucleic acid vaccine responses and which may determine their effectiveness. The microbiome is recognized as a significant regulator of immune development and response, whose role in regulating some traditional vaccine platforms has recently been discovered. Using germ-free and specific-pathogen-free mouse models in combination with different protein, DNA, and mRNA vaccine regimens, we demonstrate that the microbiome is a significant regulator of nucleic acid vaccine immunogenicity. While the presence of the microbiome enhances CD8+ T cell responses to mRNA lipid nanoparticle (LNP) immunization, the microbiome suppresses immunoglobulin and CD4+ T cell responses to DNA-prime, DNA-protein-boost immunization, indicating contrasting roles for the microbiome in the regulation of these different nucleic acid vaccine platforms. In the case of mRNA-LNP vaccination, germ-free mice display reduced dendritic cell/macrophage activation that may underlie the deficient vaccine response. Our study identifies the microbiome as a relevant determinant of nucleic acid vaccine response with implications for their continued therapeutic development and deployment.
- organism: mouse
- assay: multiome
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Vaccine Hyporesponse Induced By Individual Antibiotic Treatment In Mice And Non-Human Primates Is Diminished Upon Recovery Of The Gut Microbiome
G. Swaminathan, M. Citron, … G. D. Hannigan·bioRxiv·Apr 2, 2021
- Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responses
Emily Bettini, Aleksey Chudnovskiy, … Michela Locci·bioRxiv·May 17, 2024
- The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
S. Ndeupen, Z. Qin, … B. Z. Igyarto·bioRxiv·Mar 4, 2021
- Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunity
Xiaolei Cai, Min Chen, … Jun Huang·bioRxiv·Jan 24, 2026
- An LNP-mRNA vaccine provides potent immunogenicity and protection against Mycobacterium tuberculosis
Hannah Lukeman, Hareth A. Al-Wassiti, … Claudio Counoupas·EBioMedicinePeer-reviewed·Feb 15, 2025
- Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect